MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain health disorders, unveiled data from its Phase 2b study of MM120 (lysergide d-tartrate) for treating Generalized Anxiety Disorder (GAD) in adults. The study, known as MMED008, demonstrated both clinically and statistically significant efficacy of MM120 compared to placebo at its primary week 4 and secondary week 12 timepoints. These findings were presented at the APA Annual Meeting, the largest gathering of psychiatric professionals worldwide, held in New York City from May 4 to May 8, 2024.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for brain health disorders, revealed data from its Phase 2b trial of MM120 (lysergide d-tartrate) for Generalized Anxiety Disorder (GAD) in adults. The study, MMED008, demonstrated rapid and significant improvements compared to placebo on the Hamilton Anxiety Rating Scale (HAM-A) at the primary week 4 endpoint, with sustained efficacy up to week 12. The results were presented at the APA Annual Meeting in New York City.
Dr. Daniel R. Karlin, MindMed’s Chief Medical Officer, expressed enthusiasm for MM120’s potential based on its rapid and robust efficacy, which lasted for 12 weeks after a single dose. The 100µg dose of MM120 exhibited the most substantial clinical activity, with a notable improvement over placebo at week 12 and high clinical response and remission rates.
Furthermore, the study investigated secondary endpoints, including the Montgomery-Åsberg Depression Rating Scale (MADRS) scores, which showed significant improvements in depressive symptoms compared to placebo.
MM120 was well-tolerated, with most adverse events being mild to moderate and transient. Notably, the study design isolated MM120’s effect by tapering and washing out participants from any previous treatments.
Dr. Reid Robison, Psychiatrist and Chief Clinical Officer at Numinus, praised the study’s design for removing confounding variables, expressing confidence in the positive results and their potential benefits for patients.
In addition to presenting MM120 trial data, MindMed shared two epidemiological studies highlighting the underdiagnosis of GAD and its impact on individuals’ lives, underscoring the need for improved diagnosis and treatment options.
GAD is a prevalent condition associated with significant impairment, affecting millions worldwide. Despite its burden, there have been few innovations in GAD treatment in recent decades.
Study MMED008 was a randomized, double-blind, placebo-controlled trial evaluating the dose-response relationship of MM120 in GAD patients. The trial demonstrated MM120’s efficacy in reducing anxiety symptoms, with sustained improvements over 12 weeks.
MM120 is a novel treatment candidate for GAD, with potential applications in other brain health disorders. MindMed is committed to advancing treatments that address unmet medical needs in brain health disorders, with a mission to improve patient outcomes globally. MindMed trades on NASDAQ under the symbol MNMD.
